

Supplemental Information for Clinical Sensitivity and Interpretation of PCR and Serological COVID-19 Diagnostics for Patients Presenting to the Hospital

Supplemental methods

Setting and Design

The project was in the clinical laboratories of the Massachusetts General Hospital (MGH), a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. The study design was a retrospective review and analysis of PCR data, obtained as part of routine clinical care. The test results included in this study derived from our entire patient population tested for COVID-19, including inpatients (26%), outpatients (61%) and emergency department patients (13%). We superimposed serologic data obtained from confirmed COVID-19 positive patients as part of ongoing clinical validation studies for regulatory approval (EUA submission pending; approved by Mass General Brigham Institutional Review Board). We also used previously published data as a comparison dataset (Wölfel et al.²; see below).

Molecular Diagnostic Testing

qPCR assay. Nucleic acid testing was performed as part of clinical care at MGH using three real-time PCR assays, each of which received EUA by the FDA. Our laboratory-developed real-time PCR assay uses the Centers for Disease Control and Prevention (CDC) primers targeting regions of the N gene of SARS-CoV-2³, the cobas® SARS-CoV-2 Test performed on the cobas® 6800 (Roche) targets regions of the ORF1a and E genes, and the Xpert® Xpress SARS-CoV-2 assay run on the GeneXpert Infinity (Cepheid) targets regions of the N and E genes. Choice of which testing platform to use was determined by access to reagents available at the time of clinical testing provided for patient care. Our laboratory-developed assay was validated to detect SARS-CoV-2 at or above 5 copies/μl with 100% technical sensitivity and specificity. For commercial assays, we internally validated the assays and found 100% technical sensitivity and specificity. Within our validation cohort of known positive patients, we found 100% concordance between all 3 platforms. Despite excellent (technical) performance characteristics, pre-analytical factors such as timing during the course of infection, improper sampling, specimen handling and others may decrease the performance of viral detection.

IgM, IgG, and IgA serologic assay. An in-house enzyme-linked immunosorbent assay (ELISA) developed by Massachusetts General Hospital (Boston, MA) and the Ragon Institute of MGH, MIT, and

Harvard (Cambridge, MA), was used to measure IgG, IgA, and IgM antibodies that target the SARS-CoV-2 receptor binding domain (RBD) within the spike protein. Positive specimens were identified as those that had an optical density three standard deviations above the mean of the optical density of negative control specimens. To estimate antibody titers, we generated isotype-specific standard curves using anti-SARS-CoV-1/2 monoclonal IgG, IgA, and IgM antibodies (data not shown). Assay automation was performed on a QUANTA-Lyser 3000 (Inova). The assay has since been validated within MGH clinical laboratories as a high-complexity molecular test. The overall specificity was 98.6% for IgM, 99.0% for IgA, and 99.5% for IgG in 207 samples obtained before the pandemic (3/1/2019-1/14/2020) when no antibody responses would be expected to be detected.

Determination of date of symptom onset

The date of symptom onset was determined by review of the electronic medical record by physician investigators. The onset date was determined in by one of two ways from the medical record: 1) as explicitly defined in the chart from an MD-written note as “COVID-19+ date of symptom onset” or 2) determined from MD and non-MD notes that stated date of symptom onset for any COVID-19 related symptom that developed acutely and was new from baseline (fever, chills, loss of smell or taste, body aches, fatigue, runny nose, congestion, sore throat, cough, shortness of breath). Cases for which the date of symptom onset could not be determine were excluded from analysis (21/359, or 5.8%, of all PCR and serology cases).

Patient cohorts and statistical analysis

Clinical laboratory test results are stored in a laboratory information management system connected to the electronic medical record. We performed two data queries with different end-dates: an initial PCR-query (3/3/2020 to 4/15/2020) and a second PCR-query (3/3/2020 to 5/4/2020).

The initial PCR-query was performed to delineate clinical sensitivity over time, and analysis was restricted to patients with multiple PCR test results and at least one positive (i.e., the most informative subset). These patients were considered confirmed COVID-19 positive and taken as true positives. All PCR test results regardless of specimen type were used to confirm a patient as SARS-CoV-2 positive; however, only PCR test results from a NP-swab specimen were used for sensitivity calculations. The resulting dataset consists of 624 PCR results from 209 unique subjects. In this subset, 83% were inpatients, 13% were patients from the ED, and 4% were outpatients. For each specimen, we manually


mapped date of symptom onset and all test results on a daily scale and calculated: (a) the time (in days) from the date of symptom onset to the date of specimen collection, (b) the duration from the first positive PCR test result to any subsequent positive PCR test result, and (c) clinical detection rates (PCR positive over total tests per day) at each day in relation to symptom onset or first PCR positive, respectively. We modeled a linear daily regression trend after first positive PCR-test, to estimate the time when PCR sensitivity reaches zero (foot-point analysis).

The second PCR query was performed to capture hospital-wide testing metrics, and to assess whether the above subset analysis of SARS-CoV-2 patients with multiple PCR results is representative of the entire tested population in our setting. We extracted admission date, encounter, discharge date (when applicable), age, gender, and collection types and times, reporting dates and times along with results from all SARS-CoV-2 PCR tests. By clinical encounter, 55.5% of orders originated in the outpatient setting, 12.1% originated in the emergency department (ED), and 32.2% of orders originated from the inpatient setting. The overall PCR positivity rate was 27.0% (n=3,163/11,703) in unique individuals and 28.3% of all tests performed (n=4,320/15,251; [Table 1](#)). All test results were used for calculations of test number over time, positivity rate and age as well as gender calculations (Supplemental Figure 1 and 2).


To compare our data of mainly hospitalized patients to a population with mild disease, we used data derived from Wölfel et al.,² in which patients with a known exposure were instructed to present to the clinic at the first sign of symptoms. A positive PCR was necessary for inclusion into the study. We applied the validated limit of detection of our laboratory-developed assay (5 copies/ μ l) to the data derived from Wölfel et al.,² and used the same calculations for time-dependent clinical sensitivity for PCR.

Serologic analysis of IgM, IgA and IgG status was performed in a subset of the above SARS-CoV-2 PCR-positive patients for which we had excess material in the MGH core laboratories for clinical validation studies. For each sample, we determined the days post symptom onset at the collection date and calculated daily sensitivity for each antibody isotype as well as detection rate of any isotype. We plotted the sensitivity for both test modalities (PCR and serology) as percentages per overlapping 5-day leading intervals against the days since symptom onset. Statistical analysis consisted of Fisher's exact test (association of SARS-CoV-2 status with dichotomous factors), χ^2 with Yates correction, or t test (comparison of means).


Supplemental Figures



Supplemental Figure 1. Daily fluctuation plots of 15,251 PCR results from nasopharyngeal swabs in our hospital. During the first 61 days of PCR testing at MGH during the SARS-CoV-2 pandemic (March 3rd through May 3rd), we performed a total of 15,251 tests on samples from 11,703 unique patients (average number of tests per patient is 1.27; range: 1-9). The initial positivity rate increased over time with up to 164 positive tests (39%) per day. By total number of positive tests, and percentage tested (per day), the current peak of the pandemic in the analyzed dataset at our hospital was April 13th (Figure 1). We plotted the daily total number of specimens collected (blue line) and total number of positives (red line) (left y-axis). The right y-axis and gray line indicate the daily positivity rate. During this time there were a total of 11450 negatives and 3801 positives.




Supplemental Figure 2. Age and gender distribution of patients with NP swab PCR results (n = 11,677 patients). Stacked bar graph shows the distribution of PCR negative and PCR positive cases according to age and gender. Also shown (grey backdrop, gray bars) is the number of SARS-CoV-2 positive patients with ‘multiple’ PCR test results. *Abbreviations:* PCR, polymerase chain reaction (here for SARS-CoV-2); pos, positive; neg, negative.




Supplemental Figure 3. Swimmers plots for patients with multiple PCR results and at least 1 positive PCR. Each bar represents one patient in this cohort. A) Legend for swimmers plot bars. Bar represents patient testing time course, in days. Dark red box represents a positive NP-swab PCR, purple box indicates a PCR positive results from a non-NP swab specimen (e.g. sputum, oropharyngeal), and blue box represents a negative PCR result on that day. Patients with 2 negative PCR results and no further tests were considered negative going forward (light blue bar). B) Patient testing time course anchored on date of symptom onset, related to Figure 1. C) Patient testing time course anchored on date of first positive PCR, related to Supplemental Figure 4. Patients in gray were not included in Supplemental Figure 4 as they did not have PCR testing after the first PCR positive result.


**DETECTION RATE
(% Positives)**



Supplemental Figure 4: Detection rates by assay modality and antibody isotype over time. Blood-based serologic detection rates in 157 patients superimposed onto NP swab PCR data from 209 patients (MGH) or 9 patients (Wölfel *et al.*, Nature 2020²). Note, these are 3 independent cohorts. Results for all patient samples from initial symptom onset are plotted: MGH PCR – 516, Wölfel PCR – 152, MGH serology – 588 (196 samples x 3 isotypes). Sample results prior to day 0 were excluded. PCR and serology samples were obtained in largely different patient populations; therefore, detection rates are not additive. Serology detection rates are based on detection of IgM, IgG, or IgA individually or combined. Data is plotted as 5-day moving average against the days since symptom onset.



Supplemental Figure 5: Detection rate by PCR by day after first positive PCR. Nasopharyngeal swab PCR data from 153 patients at MGH with multiple PCR tests and at least one positive. Patients also had to have a PCR result after the first positive to be included in this cohort. As a comparator population we included data from Wölfel et al., (nature 2020)² where a positive PCR test was required at time of enrollment and all patients had multiple PCR results after first positive PCR. Footpoint analysis also included for each cohort of patients.



Supplemental Figure 6. Swimmers plots for exemplary serology cases. Each bar represents one patient in this cohort. Bar represents patient testing time course, in days. Dark red box represents a positive NP-swab PCR, purple box indicates a PCR positive results from a non-NP swab specimen (e.g. sputum, oropharyngeal), and blue box represents a negative PCR result on that day. Purple box below line indicates serology test and letter indicates the specific isotype that was positive.

Supplemental Tables

	PCR Total	PCR Negative	PCR Positive		PCR positive (multiple tests)	
Characteristics	n (% column)	n (% row)	n (% row)	P-value (row)	n (% column)	P-value vs. PCR pos.
Patients	11,698	8,540 (73)	3,163 (27)		209	
Age						
Median	46	45	47	<0.001	46	0.702
Average	47.0	46.6	48.0		48.6	
Range	0 to 102	0 to 100	0 to 102		21 to 93	
Age <20	434	357 (83.3)	77 (17.7)	<0.001	N/A	
Age ≥20	11,264	8,178 (72.6)	3,086 (27.4)		209 (100)	
Gender						
Female	6,411 (55)	4,827 (75)	1,584 (25)	<0.001	110 (53)	0.528
Male	5,270 (45)	3,694 (70)	1,576 (30)		99 (47)	
Other	22 (0.2)	19 (86)	3 (14)			
Number of Tests	15,251	10,931 (72)	4,320 (28)		549	
NP swabs	14,535 (95)	10,391 (95)	4,144 (96)	0.025	517 (94.2)	0.071
other	716 (5)	540 (5)	176 (4)		32 (5.8)	
NP/OP swab	236	130	106		6	
Sputum	222	174	48		13	
OP swab	72	62	12		11	
N/A	186	174	10		2	
Median	1	1	1		2	
Average	1.27	1.25	1.19		2.47	
Range	1 to 9	1 to 8	1 to 7		2 to 7	

Table 1. PCR cohort testing metrics and demographic data. P-values on left are derived from comparison of characteristics in the PCR positive vs. negative groups; P-values on right compare characteristics in the PCR positive (multiple tests) vs. PCR positive groups. *Abbreviation:* NP, nasopharyngeal

Characteristics	Total		Any SARS-CoV-2 antibodies		No SARS-CoV-2 antibodies		P-value
	n	157	93		64		
Age							0.017*
Average	57		55	67%	63	63%	
Median	57		55	33%	62	37%	
Range	22 to 98		27 to 93		22 to 98		
Gender							0.613
Male	102	65%	62	67%	40	63%	
Female	55	35%	31	33%	24	37%	
Days post symptom onset							<0.001
average	12		14		7		
median	10		12		7		
range	0 to 37		-5 to 37		0 to 19		

Serology (ELISA)							
			Male (% male)	Female (% female)	Age <70 (% <70)	Age ≥70 (% ≥70)	
Total specimens tested	197		132	65	151	46	
No SARS-CoV-2 antibodies	75	38%	47 (36)	28	46	29	
Any SARS-CoV-2 antibodies	122	62%	85 (64)	37	105	17	
Isotype Combinations	122		85	37	105	17	
IgM + IgG + IgA	67	55%	47 (55)	20 (54)	60 (57)	7 (41)	
IgG + IgA	13	11%	9 (11)	4 (11)	12 (11)	1 (6)	
IgM + IgG	10	8%	6 (7)	4 (11)	7 (7)	3 (18)	
IgM + IgA	3	2%	2 (2)	1 (3)	2 (2)	1 (6)	
IgM only	9	7%	6 (7)	3 (8)	7 (7)	2 (12)	
IgG only	10	8%	8 (9)	2 (5)	9 (9)	1 (6)	
IgA only	10	8%	7 (8)	3 (8)	8 (8)	2 (12)	

Supplemental Table 2. Serology sensitivities by age, gender, and date of symptom onset. Top table shown by patient, while bottom table that shows antibody isotype(s) during different disease course time points is by specimen. For patients with multiple specimens, they were considered positive if any specimen was positive. The earliest positive time point was used. *While univariate contingency analysis showed significant differences in age; this difference did not reach significance in multivariate analyses.

Sensitivity		
0 to 7 days post symptom onset	60	
Testing with IgG	9	15%
Testing with IgG + IgM	12	20%
Testing with IgG + IgM + IgA	15	25%
By Isotype (days 0 to 7)		
IgM + IgG + IgA	3	5%
IgG + IgA	3	5%
IgM + IgG	1	2%
IgM + IgA	0	0%
IgM only	3	5%
IgG only	2	3%
IgA only	3	5%
8 to 14 days post symptom onset		
8 to 14 days post symptom onset	85	
Testing with IgG	45	53%
Testing with IgG + IgM	53	62%
Testing with IgG + IgM + IgA	58	68%
By Isotype (days 8 to 14)		
IgM + IgG + IgA	30	35%
IgG + IgA	1	1%
IgM + IgG	8	9%
IgM + IgA	2	2%
IgM only	6	7%
IgG only	6	7%
IgA only	5	6%
>14 days post symptom onset		
>14 days post symptom onset	52	
Testing with IgG	46	88%
Testing with IgG + IgM	47	90%
Testing with IgG + IgM + IgA	49	94%
By Isotype (>14 days)		
IgM + IgG + IgA	34	65%
IgG + IgA	9	17%
IgM + IgG	1	2%
IgM + IgA	1	2%
IgM only	0	0%
IgG only	2	4%
IgA only	2	4%

Supplemental Table 3. Sensitivity by all combinations of antibody isotypes during different disease course time points.

Author contributions:

Conception and design: T.E.M. W.F.G.B, A.Z.B., T.G., E.S.R., J.L.

Analysis and interpretation of the data: T.E.M., W.F.G.B, A.Z.B., T.G., M.N.A., V.M.P., M.R.M., A.J.I., E.S.R., J.L.

Drafting of the article: T.E.M., W.F.G.B, J.L.

Critical revision for important intellectual content: T.E.M., W.F.G.B, A.Z.B., T.G., M.N.A., J.A.G., M.C.P., B.E.B., D.N.L., A.D., R.C.C., E.T.R., V.M.P., M.R.M., A.J.I., E.S.R., J.L.

Final approval of the article: T.E.M. W.F.G.B, A.Z.B., T.G., M.N.A., M.G.A., D.Y., J.T., A.S.F., G.K.M., M.J.F., V.N., J.F., B.M.H., T.M.C., H.D.M., L.L.R., S.E.T., J.B., N.Z.G., G.A., A.G.S., J.B.H., J.A.G., M.C.P., B.E.B., D.N.L., A.D., R.C.C., E.T.R., J.A.B., V.M.P., M.R.M., A.J.I., E.S.R., J.L.

Provision of study materials or patients: J.F., B.M.H., T.M.C., G.A., A.G.S., J.B.H., R.C.C., E.T.R.,

Administrative, technical, or logistic support: J.T., H.D.M., L.L.R., S.E.T., J.B., N.Z.G., D.N.L., A.D.

Collection and assembly of data: T.E.M. W.F.G.B, A.Z.B., T.G., M.N.A., M.G.A., D.Y., J.T., A.S.F., G.K.M., M.J.F., V.N., A.D., R.C.C., E.T.R., J.A.B., V.M.P., M.R.M., A.J.I., E.S.R., J.L.